Participating Companies

AM-Pharma B.V.
Results from Ph 2 in 300+ pts demonstrated improvement of 40%+ OS in recAP group. Initiated Ph 3 in Q4 2020; TL safety & futility analysis on first 400 pts exp YE2021. Expects to complete tgt enrollment & announce primary endpoint data of 28-day all-cause mortality in 2023. [more information]

Anima Biotech
We develop a pipeline across therapeutic areas and partner with Pharma for their targets including our $1B+ collaboration with Lilly for the discovery and development of translation inhibitors of several targets. [more information]

Apexigen
CD40 agonist mAb; 170+ pts dosed (mono & combi settings). 7 ongoing Ph 2s, undisclosed ocular disease program in Ph 3. AACR: Ph 1b data (w/Parker Inst); collabs w/BMY, MDACC, Yale, et al [more information]

Apic Bio
Developer of a gene therapy proprietary platform intended to treat rare diseases with complex mechanisms. The company's platform offers APB-101 which targets the liver by way of an AAV delivered Dual Function Vector, enabling doctors to treat rare, devastating neurological and liver diseases. [more information]

AsclepiX Therapeutics
AXT107 demonstrated efficacy and durability in rabbit and mouse models that is superior to standard of care Eylea. [more information]

ATAI Life Sciences AG
ATAI is a global biotech company builder that leverages a decentralized, technology- and data-driven platform model to serve millions of people suffering from mental health disorders. ATAI is committed to acquiring and efficiently developing innovative treatments that address significant unmet medical needs and lead to paradigm shifts in the mental health space. [more information]

AUM Biosciences
AUM is a global biopharmaceutical company aiming to democratize R&D with a focus on discovering, acquiring, and developing novel therapeutics in oncology. [more information]

Axial Biotherapeutics, Inc.
The company's biotherapeutics products harness the gut-brain axis to develop novel Central Nervous System (CNS) Therapeutics to improve the quality of life for people with CNS diseases and disorders, providing medical professionals and healthcare institutions with a new approach for diagnosing and treating PD and ASD and potentially other CNS diseases. [more information]

Azitra
The company leverages microbiological bacteria strains technology to facilitate the treatment of eczema, ichthyosis vulgaris, inflammatory skin, irritated skin and orphan skin diseases including Netherton syndrome, enabling dermatologists to treat patients with chronic and acute skin disorders [more information]

Boundless Bio
Developer of novel cancer therapeutics intended to understand and treat intraceable cancers. The company is in the process of developing a novel class of cancer drugs and extrachromosomal DNA (ecDNA) that eliminates cancer cells ability to employ ecDNA to survive, enabling healthcare professionals to treat most-difficult cancers. [more information]

CalciMedica
Focused on CRAC channel for the treatment of acute and severe inflammatory diseases. CalciMedica’s lead compound Auxora has delivered promising Phase 2 results in severe COVID-19 pneumonia and acute pancreatitis. A Phase 2/3 clinical trial of Auxora in up to 400 patients with severe COVID-19 pneumonia is ongoing, and a Phase 2b trial of Auxora in patients with acute pancreatitis and a dose escalating phase 2 study in ventilated ARDS patients with COVID-19 and other pneumonia are expected to commence soon. [more information]

Candesant Biomedical
Candesant Biomedical is developing a compelling product to unlock the potential of the sweat control market. Further, the product will provide a great value to the consumer with an economic incentive to the treating physicians. [more information]

Cellestia Biotech AG
The company's drugs offer a mode of action for the treatment of NOTCH dependent leukemias, lymphomas and solid tumors through oral medication, enabling patients to get efficient treatment and ensure a fast recovery. Cellestia is completing a Phase l first-in-man clinical trial with CB-103 treating cancer patients in the EU. [more information]

CerSci Therapeutics
Developing a new generation of non-opioid medicines to treat acute post-operative and chronic neuropathic pain. Lead program in Phase 1 (MAD/SAD/Food Effect), CT-044, targeting reactive species that cause neuronal ion channel hyper-sensitization, known to trigger pain. [more information]

Clerio Vision, Inc.
Novel ophthalmic technology to treat refractive error addressing multi-billion markets in contact lenses (presbyopia) and corneal vision correction (non surgical flapless laser solution). Based on Nobel Prize winning femto-second laser technology developed by Bausch & Lomb and the University of Rochester. [more information]

Diasome
Developer of novel and cell targeted therapies designed to treat diabetes, obesity and other metabolic conditions. The company's therapies include ISLE-1 (InSulin Liver Effect) Phase 2b study of HDV-Insulin in subjects with Type 1 diabetes, enabling patients to get novel proprietary liver targeted insulins for both Type 1 and Type 2 diabetes easily. [more information]

Enterin
Developer of novel drugs intended to repair the dysfunctional gut-brain axis. The company's drugs displaces α-synuclein aggregates and restores normal signaling between the gut and the brain, enabling patients with Parkinson's disease and other neurodegenerative conditions to have a better the quality of life. [more information]

EOC Pharma
EOC is a Shanghai-based biopharmaceutical company that is focused on the in-licensing of innovative global oncology products, and developing, manufacturing and commercializing them for the China market. [more information]

Faraday Pharmaceuticals
Chronic and acute agents to prevent cardiac and skeletal muscle loss by modulating neurohumoral pathways and restoring metabolic flexibility: lead candidate FDY-5301 Ph 3 ready for reperfusion injury following heart attack (AMI). $57M raised to date from Arch Venture Partners, Polaris Partners, WRF, Osage [more information]

Forbius
Selective inhibitors of TGF Beta & EGFR pathways. AACR: (+) Ph 1 data. 3 ongoing Ph 2 trials (SCCHN, NSCLC, TNBC); addl Ph 1 trials in IO, Systemic Sclerosis & Myelofibrosis [more information]

HemoShear Therapeutics
HemoShear Therapeutics discovers novel biological targets and advances drug programs to treat metabolic disorders with significant unmet patient need. The Company's lead programs in propionic and methylmalonic acidemia (rare inborn errors of metabolism) will enter phase 2 studies this year. [more information]

Incysus Therapeutics
The company's services focus on utilizing genetically modified gamma-delta T cells across a Drug Resistance Immunotherapy (DRI) platform that addresses the challenges faced while targeting cold, low mutation cancers, enabling the targeting of malignant cells and potentially more effective treatments for patients with difficult-to-treat solid tumor cancers. [more information]

ISA Pharmaceuticals BV
is an immunotherapy company developing rationally designed, fully synthetic immunotherapeutics against cancer and persistent viral infections. The Company has built a proprietary immunotherapy platform based on the Synthetic Long Peptide (SLP®) concept and AMPLIVANT®technology. [more information]

jCyte
Developer of cell-based technology intended to cure retinitis pigmentosa. The company's therapy used retinal progenitor cells can secrete growth factors to rescue damaged retinal cells which helps in treating a degenerative eye disease that ultimately causes blindness enabling, patients afflicted by conditions that lead to blindness, preserve and restore sight. [more information]

Juvenescence
Developer of therapies and technologies designed to treat diseases of aging and increase human longevity. The company's technologies help patients to eradicate life-shattering diseases that cause people to suffer until death, enabling patients to halt or potentially reverse elements of ageing. [more information]

KAHR
The company lead product, DSP107, is a CD47-41BB targeting compound that simultaneously target cancer cells, weaken their innate defenses and activate an effective, local response of both innate (by blocking ‘Don’t eat me’ signals) and adaptive immunity (by providing co-stimulation signal to T and NK cells). [more information]

Kineta Inc.
Kineta (Private) - wholly owned preclinical anti-VISTA (innate immune target) antibody reprograms the tumor microenvironment and is differentiated from other immunotherapies by blocking suppressive cells in cold tumors. $360M+ deal with Genentech for KCP506, Ph1 non-opioid for chronic pain. [more information]

Maverick Therapeutics
Maverick Therapeutics is a biotech company focused on improving the lives of patients with solid tumor cancers by developing breakthrough T cell immunotherapies with improved safety and efficacy. [more information]

Minoryx Therapeutics
Oral PPARg agonist, MIN-102, in Pivotal Ph 2/3 for X-linked ALD and Ph 2 Friedrich’s Ataxia; data for both expected by end of 2020. VC investors include Kurma, Ysios, Fund+, Roche, Idinvest, etc
[more information]

Neurana Pharmaceuticals
The primary objective of the study was to assess the efficacy of various daily doses of tolperisone to determine the dose to be used for the planned Phase 3 clinical program. Given the positive results of the STAR Study, Neurana plans to conduct an end-of-Phase 2 meeting with the FDA in the first quarter of 2020 and initiate Phase 3 clinical studies of tolperisone later in 2020. [more information]

NorthSea Therapeutics
First-in class, oral, structurally engineered fatty acids [SEFAs] addressing NASH and associated metabolic disorders via unique targeting of pathways regulating metabolism, oxidative stress, inflammation, and fibrosis. $40m Series B (Jan 2020) with venBio Partners (lead) and Sofinnova Investments. [more information]

Notch Therapeutics
Notch’s technology platform uses genetically tailored stem cells as a renewable source for creating allogeneic T cell therapies that expand treatment options and has the potential to deliver safer, consistently manufactured and more cost-effective cell immunotherapies to patients. [more information]

Numab Therapeutics
We are writing the next chapter in cancer immunotherapy by creating multi-specific antibodies that enable the pursuit of novel therapeutic strategies. With our proprietary MATCH™ technology platform we are fueling a new wave of multi-specific drug candidates engineered with versatility and developability in mind. [more information]

Oculis Pharma
The company's novel eye-drop treatments are based on its proprietary solubilizing nanoparticle (SNP) technology that improves both the ability to formulate drugs as eye drops and their bioavailability in the eye tissues including both the front and the back of the eye, enabling hospitals to provide clients with technological advancement in ocular drug delivery. [more information]

OnKure Therapeutics, Inc.
Developing epigenetic cancer therapies including HDAC inhibitors. Lead asset OKI-179 is a class 1 HDAC inhibitor in Ph 1. [more information]

Pipeline Therapeutics
The company also has a portfolio of programs addressing a range of neurological disorders, including development candidate PIPE-307 which is focused on remyelination to treat multiple sclerosis. [more information]

Sensei Biotherapeutics
The company is using its proprietary drug discovery platform, called SPIRIT, to discover and develop both vaccines and T-cell therapies, including SNS301, its clinical stage cancer vaccine, and SNS-723, its cell therapy program in preclinical development for solid tumors and hematological cancers. [more information]

Solebury Capital
Solebury Capital LLC is a global advisory firm and registered broker dealer exclusively focused on the equity capital markets. We provide our corporate and financial sponsor clients with independent advice, experienced judgment and transaction management services – empowering them to make more fully informed decisions at all points in the underwriting process. [more information]

Solebury Trout
With almost two decades of experience in the biotechnology, pharmaceutical, medical technology and life science technology sectors, the Trout Group offers its clients the knowledge base needed to clarify investment themes and leverage key relationships for increased exposure to the proper audience. [more information]

SphingoTec GmbH
The tests are being implemented on the Company’s own point-of-care immunoassay analyzer platform acquired form Samsung in 2018 that is fully developed and was originally launched in 2012 and was sold more than 1,800 times since then. [more information]

Spruce Biosciences
[SPRB]
US$487 MM MCap
The company’s lead product candidate, tildacerfont, is an investigational oral drug that is being evaluated in studies for the treatment of congenital adrenal hyperplasia (CAH). The company also plans to evaluate tildacerfont in other diseases impacted by elevated ACTH or adrenal androgens. [more information]

TAE Life Sciences
TAE Life Sciences is an early-stage biotechnology company developing comprehensive target drugs and neutron technology product portfolio to enable next-generation boron neutron capture therapy (BNCT) as a first-line treatment for patients globally, providing a paradigm shift in radiation therapy [more information]

Teon Therapeutics
Pipeline of next-generation cancer therapeutics targeting GPCRs including a highly-specific A2B antagonist and EP4 antagonist, both slated to enter Phase 1b trials in 2021. [more information]

Vaccitech Limited
Proprietary ChAdOx (prime) and MVA (boost) technology platform induces and maintains CD8+ T-cells at the maximum levels published to date. Ph1/2 data for HPV and HBV immunotherapies expected 2H20. Encouraging prostate cancer, 5T4 immunotherapeutic data recently released. Ph1/2 NSCLC MAGE-NYESO immunotherapeutic enters clinic in Q1 2021. ChAdOx COVID-19 vaccine out-licensed to Oxford Uni/AstraZeneca with post-pandemic revenue stream. $150M funding at Jenner Institute and company raised $48M since formation [more information]

ViaCyte, Inc.
The PEC-Direct™ product candidate delivers the pancreatic progenitor cells in a non-immunoprotective device and is being developed for type 1 diabetes patients who have hypoglycemia unawareness, extreme glycemic lability, and/or recurrent severe hypoglycemic episodes. [more information]

Viramal Limited
Viramal is an emerging specialty pharmaceutical company focused on the development of global therapeutics that improve the quality of women’s health worldwide. The company is developing innovative products that target unmet therapeutic areas through the use of its unique pharmaceutical delivery platforms and technologies. [more information]

Vor Biopharma
These eHSCs lead to generations of new healthy blood cells and the eHSCs can continue functioning normally because they are effectively hidden from the therapies that target the relevant protein. In contrast, diseased cells retain the target protein and are vulnerable to attack. [more information]

Zikani Therapeutics
Zikani Therapeutics is using its innovative chemistry technology platform to develop novel Ribosome Modulating Agents (RMAs). Zikani’s TURBO-ZM platform allows rapid synthesis of novel compounds that can be optimized to modulate the human ribosome in a disease specific manner. [more information]